Also, in patients with asthma and obesity, anti-IL-5 biologics may have limited effectiveness due to their specific effects on eosinophil maturation, activation, survival, and recruitment to the airway (Padilla Galo et al., 2018; Cinqair, 2023). The gene discussed is IL5; the disease is Obesity.